Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

PRFX

PainReform (PRFX)

PainReform Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:PRFX
日付受信時刻ニュースソース見出しコード企業名
2025/02/1822 : 42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2025/02/1822 : 30GlobeNewswire Inc.PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion OpportunityNASDAQ:PRFXPainReform Ltd
2025/01/0306 : 15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRFXPainReform Ltd
2025/01/0306 : 06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/12/2722 : 58Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/12/2722 : 30GlobeNewswire Inc.PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110NASDAQ:PRFXPainReform Ltd
2024/12/1314 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
2024/12/1307 : 00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PRFXPainReform Ltd
2024/12/0706 : 30Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRFXPainReform Ltd
2024/12/0506 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/11/2022 : 50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/11/2022 : 30GlobeNewswire Inc.PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNASDAQ:PRFXPainReform Ltd
2024/11/1907 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/11/1222 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/11/0807 : 00GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNASDAQ:PRFXPainReform Ltd
2024/11/0806 : 59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/11/0506 : 39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/10/1705 : 35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/10/1705 : 30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRFXPainReform Ltd
2024/10/1106 : 25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/10/0413 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
2024/10/0105 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/09/2105 : 30Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRFXPainReform Ltd
2024/09/1122 : 36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/09/1121 : 30GlobeNewswire Inc.PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110NASDAQ:PRFXPainReform Ltd
2024/09/1022 : 46GlobeNewswire Inc.PainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsNASDAQ:PRFXPainReform Ltd
2024/09/1022 : 13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/09/0505 : 16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
2024/08/3013 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
2024/08/2905 : 30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:PRFXPainReform Ltd
 Showing the most relevant articles for your search:NASDAQ:PRFX